A General Statistic to Test an Optimally Weighted Combination of Common and/or Rare Variants

Abstract

AbstractBoth genome-wide association study and next generation sequencing data analyses are widely employed in order to identify disease susceptible common and/or rare genetic variants in many large scale genetic studies. Rare variants generally have large effects though they are hard to detect due to their low frequency. Currently, many existing statistical methods for rare variants association studies employ a weighted combination scheme, which usually puts subjective weights or suboptimal weights based on some ad hoc assumptions (e.g. ignoring dependence between rare variants). In this study, we analytically derive optimal weights for both common and rare variants and propose a General and novel approach to Test association between an Optimally Weighted combination of variants (G-TOW) in a gene or pathway for a continuous or dichotomous trait while easily adjusting for covariates. We conduct extensive simulation studies to evaluate the performance of G-TOW. Results of the simulation studies show that G-TOW has properly controlled type I error rates and it is the most powerful test among the methods we compared, when testing effects of either both rare and common variants or rare variants only. We also illustrate the effectiveness of G-TOW using the Genetic Analysis Workshop 17 (GAW17) data. In addition, we applied G-TOW and other competitive methods to test association for schizophrenia. The G-TOW have successfully verified genes FYN and VPS39 which are associated with schizophrenia reported in existing publications. Both of these genes are missed by the weighted sum statistic (WSS) and the sequence kernel association test (SKAT). G-TOW also showed much stronger significance (p-value=0.0037) than our previously developed method named Testing the effect of an Optimally Weighted combination of variants (TOW) (p-value=0.0143) on gene FYN. FYN is a member of the protein-tyrosine kinase oncogene family that phosphorylates glutamate metabotropic receptors and ionotropic N-methyl-d-aspartate (NMDA) receptors. NMDA modulates trafficking, subcellular distribution and function. It is involved in neuronal apoptosis, brain development and synaptic transmission and lower expression, which has been observed in the platelets of schizophrenic patients compared with controls. The application for schizophrenia indicates that G-TOW is a powerful tool in genome-wide association studies.